Digestive Diseases and Sciences

, Volume 55, Issue 5, pp 1413–1420

Impact of Concomitant Immunomodulator Use on Long-Term Outcomes in Patients Receiving Scheduled Maintenance Infliximab

Authors

  • Alan C. Moss
    • Harvard Medical School, Beth Israel Deaconess Medical CenterCenter for Inflammatory Bowel Disease
  • Kyung Jo Kim
    • Harvard Medical School, Beth Israel Deaconess Medical CenterCenter for Inflammatory Bowel Disease
  • Nielsen Fernandez-Becker
    • Harvard Medical School, Beth Israel Deaconess Medical CenterCenter for Inflammatory Bowel Disease
  • Didia Cury
    • Harvard Medical School, Beth Israel Deaconess Medical CenterCenter for Inflammatory Bowel Disease
    • Harvard Medical School, Beth Israel Deaconess Medical CenterCenter for Inflammatory Bowel Disease
Original Article

DOI: 10.1007/s10620-009-0856-7

Cite this article as:
Moss, A.C., Kim, K.J., Fernandez-Becker, N. et al. Dig Dis Sci (2010) 55: 1413. doi:10.1007/s10620-009-0856-7

Abstract

The long-term benefits of combining scheduled infliximab with concomitant immunomodulators [azathioprine or 6-mercaptopurine (6-MP)] in patients with Crohn’s disease are unclear. Historical cohort followed for 5 years after initiation of infliximab for active Crohn’s disease. Data were available on 123 patients who received scheduled maintenance infliximab infusions, for up to 5 years after initiation of infliximab. Clinical remission rates in the entire cohort were 73% (82/113) at 1 year, 65% (65/100) at 2 years, and 58% (21/36) at 5 years. Remission rates with maintenance infliximab were significantly improved in those receiving concomitant immunomodulators at 1 year (86% versus 68%, P = 0.03), but not at 2 years (80% versus 72%, P = 0.4). In a multivariate logistic regression model, concomitant immunomodulator use was not associated with a significantly improved odds ratio of remission in patients on maintenance infliximab [odds ratio (OR) 1.1, 95% confidence intervals (CI) 0.9–1.2, P = 0.9]. The risk of surgery was significantly reduced in those receiving immunomodulators at the commencement of maintenance infliximab (OR 0.3, 95% CI 0.1–0.7, P = 0.01), but not in patients who continued maintenance concomitant therapy (OR 0.4, 95% CI 0.1–1.5, P = 0.1). The combination of maintenance infliximab and an immunomodulator produced modest improvements in outcomes beyond maintenance infliximab alone in this cohort.

Keywords

Crohn’s diseaseInfliximabAzathioprineOutcomes

Copyright information

© Springer Science+Business Media, LLC 2009